• Publication Date: 04/01/2023
  • Author(s):
    Goodacre, Lucy Forbes, Ben Lansley, Alison Patterson, Claire Roe, Chris
  • Organization(s):
    King’s College London Quotient Sciences SEDA Pharmaceutical Development University of Brighton
  • Article Type: Back Page
  • Subjects: Industry Issues and Trends, Nasal Delivery

The Biopharmaceutics Focus Group of the Academy of Pharmaceutical Sciences (APS) of Great Britain presented a workshop on nasal biopharmaceutics at the 2022 Drug Delivery to the Lungs Conference (DDL2022) in December 2022 in Edinburgh, UK. The aim was to bring together the scientific community to discuss challenges in the development of nasally administered therapies.

The workshop featured thought-provoking talks on six topics: nasal drug product characterization, physiologically-based biopharmaceutics modeling (PBBM), modeling deposition in the nasal cavity, in vitro biological characterization, nonclinical studies and clinical development. The speakers summarized how biopharmaceutics and performance of nasal products are currently evaluated and shared their thoughts on new developments and unmet needs. The workshop concluded with a facilitated panel discussion that explored opportunities and challenges in these areas.

Download PDF